Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Conditions
Brief summary
This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
Detailed description
PRIMARY OBJECTIVE: I. To estimate the progression-free survival (PFS) hazard ratio of trametinib compared to that of commercially available therapies consisting of one of five commercially available agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum previously treated with platinum-based chemotherapy. SECONDARY OBJECTIVES: I. To determine the nature, frequency and maximum degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 for each treatment arm. II. To determine the quality of life, as assessed by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O). IIa. To compare trametinib to the control arm with regard to patients' self-reported acute (up to post-cycle 6) quality of life as measured by the FACT-O-Trial Outcome Index (TOI). IIb. To compare trametinib to the control arm with regard to patients' self-reported acute (up to post-cycle 6) neurotoxicity as measured by the FACT-Gynecologic Oncology Group (GOG)-Neurotoxicity (NTX). III. To estimate the objective response rate (RR) of patients in each treatment arm. IV. To test whether high expression of pERK, as quantified by immunohistochemistry (IHC), is associated with better prognosis (RR or PFS) among patients receiving the randomized treatment. V. To test whether genetic changes associated with MAPK pathway activation (KRAS, NRAS, HRAS, BRAF, MEK, ERBB2 or NF1) are associated with improved prognosis (RR or PFS) among patients receiving the randomized treatment. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive clinician's choice of either letrozole orally (PO) once daily (QD) on days 1-28, tamoxifen citrate PO twice daily (BID) on days 1-28, paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride (PLD) IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B. ARM B: Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.
Interventions
DRUGLetrozole
Given PO
DRUGPaclitaxel
Given IV
DRUGPegylated Liposomal Doxorubicin Hydrochloride
Given IV
OTHERQuality-of-Life Assessment
Ancillary studies
OTHERQuestionnaire Administration
Ancillary studies
DRUGTamoxifen Citrate
Given PO
DRUGTopotecan
Given IV
Given PO
Sponsors
NRG Oncology
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients age greater than 18 with the following tumors are included in the study: * Patients initially diagnosed with low-grade serous ovarian or peritoneal carcinoma that recur as low-grade serous carcinoma (invasive micropapillary serous carcinoma or invasive grade I serous carcinomas as defined by GOG, Federation of Obstetricians and Gynecologists \[FIGO\], World Health Organization \[WHO\] or Silverberg) * Patients initially diagnosed with serous borderline ovarian or peritoneal carcinoma that recur as low-grade serous carcinoma (invasive micropapillary serous carcinoma or invasive grade I serous carcinomas as defined by GOG, FIGO WHO or Silverberg) * At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g. MAJOR: laparotomy, laparoscopy, thoracotomy, VATS \[video assisted thorascopic surgery\]); there is no restriction on MINOR procedures: (e.g. central venous catheter placement, ureteral stent placement or exchange, tumor core or fine-needle aspirate \[FNA\] biopsy) * Patients must have documented low-grade serous carcinoma; confirmation must occur by prospective pathology review prior to study entry; the prospective pathology review can be done on tissue from the recurrent carcinoma or from original diagnostic specimen * All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one target lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be \>= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or \>= 20 mm when measured by chest x-ray; lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI; all imaging studies must be performed within 28 days prior to registration * Prior therapy * Patients must have recurred or progressed following at least one platinum-based chemotherapy regimen * Patients may have received an unlimited number of prior therapy regimens * Patients may not have received all of the five choices in the standard therapy arm * Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration * Any other prior therapy directed at the malignant tumor, including chemotherapy and radiation therapy, must be discontinued at least 4 weeks prior to registration; any investigational agent must be discontinued at least 28 days prior to registration * Trametinib, can cause fetal harm when administered to a pregnant woman; women of child-bearing potential (i.e. patients whose reproductive organs remain in place and who have not passed menopause) and men must agree to use a highly effective method of contraception (e.g. hormonal, intrauterine device or; abstinence\*) prior to study entry, during the study participation, and for six months after the last dose of the drug; women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to randomization, cannot be breast-feeding, and must agree to use a highly effective form of contraception throughout the treatment period and for 6 months after the last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Abstinence is only acceptable when this is in line with the preferred and usual lifestyle of the patient * Patients must have the ability to understand and sign an approved informed consent and authorization permitting release of personal health information * Patients must have a GOG performance status of 0 or 1 * Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome, bowel obstruction, or major resection of the stomach or bowel * All prior treatment-related toxicities must be CTCAE v4 grade =\< 1 (except alopecia) at the time of randomization * Patients must have a left ventricular ejection fraction \>= lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA) * Serum creatinine =\< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) \>= 50 mL/min OR 24-hour urine creatinine clearance \>= 50 mL/min (within 14 days prior to treatment) * Bilirubin =\< 1.5 times upper limit of normal (within 14 days prior to treatment) * Alanine aminotransferase (ALT) =\< 2.5 times upper limit of normal (within 14 days prior to treatment) * Aspartate aminotransferase (AST) =\< 2.5 times upper limit of normal (within 14 days prior to treatment) * Albumin \>= 2.5 g/dL (within 14 days prior to treatment) * Prothrombin time (PT) and activated partial thromboplastin time (APTT) =\< 1.5 times upper limit of normal (within 14 days prior to treatment) * Neutrophil count \>= 1.5 x 10\^9/L (within 14 days prior to treatment) * Platelet count \>= 100 x 10\^9/L (within 14 days prior to treatment) * Hemoglobin \>= 9.0 g/dL (within 14 days prior to treatment) * If letrozole is selected as the control therapy, patients must be postmenopausal, either following bilateral oophorectomy or at least 5 years after spontaneous menopause; patients within 5 years of spontaneous menopause or who have had a hysterectomy without bilateral oophorectomy must have postmenopausal luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels; patients on hormone replacement therapy (HRT) must agree to withdrawal of hormone therapy before letrozole is started
Exclusion criteria
* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib or standard of care agent * If patients have had a potential index lesion radiated, it must have progressed post radiation therapy to be used as a measurable eligibility lesion * Patients may not have received prior MEK, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor therapy * Current use of a prohibited medication; the following medications or non-drug therapies are prohibited: * Patients may not be receiving any other anti-cancer or investigational agents * Because the composition, PK, and metabolism of many herbal supplements are unknown, the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to St. John's wort, kava, ephedra \[ma huang\], gingko biloba, dehydroepiandrosterone \[DHEA\], yohimbe, saw palmetto, or ginseng) * Patients with known leptomeningeal or brain metastases or spinal cord compression should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * Patients with a bowel obstruction or any other gastrointestinal condition that might affect absorption of the oral drug should be excluded; this would include patients with inability to swallow and retain orally-administered medication, malabsorption syndrome, or those with a major resection of the stomach or bowels * Patients with a history of interstitial lung disease or pneumonitis * Patients with a previous or current malignancy at other sites should be excluded, with the exception of: * Curatively treated local tumors such as carcinoma-in-situ of the cervix, basal or squamous cell carcinoma of the skin * Tumors for which no relapse has been observed within 5 years * Known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients, or to dimethyl sulfoxide (DMSO), or to Cremophor EL (polyoxyethylated castor oil); please note, exclusion for Cremophor is unnecessary unless paclitaxel is the only agent available and the patient randomizes to the conventional therapy option * Patients with a history or evidence of cardiovascular risk, including any of the following: * Left ventricular ejection fraction (LVEF) \< lower limit of normal (LLN) * Bazett's corrected QT (QTcB) \>= 480 msec * History or evidence of current clinically significant uncontrolled arrhythmias * Exception: Subjects with controlled atrial fibrillation for \> 30 days prior to randomization are eligible * History of (within 6 months prior to randomization) acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting * History or evidence of current \>= class II congestive heart failure as defined by New York Heart Association (NYHA) * Treatment refractory hypertension defined as a blood pressure of systolic \> 140 mmHg and/or diastolic \> 90 mmHg which cannot be controlled by anti-hypertensive therapy * Patients with intra-cardiac defibrillators or permanent pacemakers * Known cardiac metastases * Patients with a history or current evidence/risk of retinal vein occlusion (RVO) * Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures * Patients who require use of a concomitant medication that can prolong the QT interval * Animal reproductive studies have not been conducted with trametinib; therefore, the study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B | Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the PFS endpoint definition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Time from study entry to time of death or date of last contact, an average of 29 months for arm A and 37 months for arm B | Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact. Patients with disease progression on the Control arm were allowed to cross over to the trametinib arm. Per the protocol, the intent-to-treat OS analysis was not adjusted for crossover. |
| Objective Tumor Response Rate (Complete Response and Partial Response) | Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B | The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria. |
| Patients Reported Acute Quality of Life | 1. baseline (prior to cycle 1), 12 weeks (prior to cycle 4), 24 weeks (4 weeks post cycle 6), 36 weeks post cycle 1, 52 weeks post cycle 1. | Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for ovarian cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). . The FACT-O TOI score is calculated as the sum of the subscale scores if more than 80% of the FACT-O TOI items provide valid answers and all of the component subscales have valid scores. The FACT-O TOI score ranges 0-100 with a large score suggesting better QOL. Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the quality of life endpoint definition |
| Incidence of Adverse Events (AEs) | During treatment period and up to 100 days after stopping the study treatment | Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy. Excludes AEs observed among control patients treated with trametinib after crossover.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the AE endpoint definition. |
| Progression Free Survival | Time from study entry to time of progression or death, an average of 7 months for SOC and 13 months for the treatment (Trametinib) arm. | Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan. RECIST v1.1 defines progression as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. |
| pERK Expression | Baseline | Will be quantified using the H-score derived from the immunohistochemistry analysis of patient tumor tissue and is expected to present as a continuous measure. will consider the prognostic and predictive abilities of pERK relative to objective response rate (ORR) or PFS. Analysis of the dichotomous markers will be supported by Kaplan Meier plots, and forest plots of the odds-ratio and hazard ratio estimates. Duration of response will be depicted using swimmer plots, with median duration estimated using Kaplan Meier methods. The multivariable models will include covariate adjustment for geographic region, performance status and number of prior regimens, presented using effect coding. The adjusted hazard- and odds- ratio estimates from the multivariable models will be supported by nominal p-values and 2-sided, 95% confidence intervals. Confidence intervals will be interpreted as the plausible range of values for the true (unobserved) ratio that is supported by the data. |
| Patient Reported Acute Peripheral Neuropathy Symptoms | Up to 52 weeks | Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggesting less peripheral neuropathy symptoms |
Countries
United Kingdom, United States
Participant flow
Recruitment details
A total of 260 patients enrolled before accrual closed on 04/10/2018.
Participants by arm
| Arm | Count |
|---|---|
| Arm A - Control Arm Investigators choice of Letrozole 2.5 mg po qd continuously, tamoxifen 20mg po bid continuously, paclitaxel 80mg/m2 IV over 1 hr on day 1q 7d, 3 wks on, 1 wk off, Pegylated Liposomal Doxorubicin 40 or 50mg/m2 IV over 1 hr on day 1 q. 28d, Topotecan 4.0mg/m2 over 30 min on day 1,8 and 15 of a 28 day cycle. For each arm, 1 cycle - 28 days | 130 |
| Arm B - Experimental Arm Trametinib 2 mg po daily continuous treatment, For each arm, 1 cycle = 28 days | 130 |
| Total | 260 |
Baseline characteristics
| Characteristic | Total | Arm A - Control Arm | Arm B - Experimental Arm |
|---|---|---|---|
| Age, Continuous | 53.7 years STANDARD_DEVIATION 14.1 | 53.89 years STANDARD_DEVIATION 14.03 | 53.57 years STANDARD_DEVIATION 14.13 |
| Age, Customized 20-29 years | 19 Participants | 9 Participants | 10 Participants |
| Age, Customized 30-39 years | 34 Participants | 18 Participants | 16 Participants |
| Age, Customized 40-49 years | 43 Participants | 21 Participants | 22 Participants |
| Age, Customized 50-59 years | 63 Participants | 28 Participants | 35 Participants |
| Age, Customized 60-69 years | 72 Participants | 39 Participants | 33 Participants |
| Age, Customized >= 70 years | 29 Participants | 15 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 15 Participants | 7 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 236 Participants | 118 Participants | 118 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 9 Participants | 5 Participants | 4 Participants |
| Number of Prior Treatment Regimens 1 Prior Treatment Regimens | 59 Participants | 30 Participants | 29 Participants |
| Number of Prior Treatment Regimens 2 Prior Treatment Regimens | 76 Participants | 37 Participants | 39 Participants |
| Number of Prior Treatment Regimens 3 or More Prior Treatment Regimens | 125 Participants | 63 Participants | 62 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 4 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 9 Participants | 5 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 4 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 14 Participants | 7 Participants | 7 Participants |
| Race (NIH/OMB) White | 229 Participants | 114 Participants | 115 Participants |
| Region of Enrollment United Kingdom | 55 participants | 28 participants | 27 participants |
| Region of Enrollment United States | 205 participants | 102 participants | 103 participants |
| Sex: Female, Male Female | 260 Participants | 130 Participants | 130 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 60 / 127 | 51 / 127 | 3 / 88 |
| other Total, other adverse events | 124 / 127 | 127 / 127 | 88 / 88 |
| serious Total, serious adverse events | 43 / 127 | 45 / 127 | 25 / 88 |
Outcome results
Primary
Progression-free Survival (PFS)
Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the PFS endpoint definition.
Time frame: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B
Population: All randomized patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A - Control Arm | Progression-free Survival (PFS) | 7.2 months |
| Arm B - Experimental Arm | Progression-free Survival (PFS) | 13.0 months |
Secondary
Incidence of Adverse Events (AEs)
Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy. Excludes AEs observed among control patients treated with trametinib after crossover.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the AE endpoint definition.
Time frame: During treatment period and up to 100 days after stopping the study treatment
Population: Treated with randomized therapy
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Nausea | 14 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Hypertension | 6 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Abdominal pain | 22 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Anemia | 12 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Diarrhea | 4 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Fatigue | 5 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Neutrophil count decreased | 1 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Rash maculo-papular | 0 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Small Intestinal Obstruction | 9 participants |
| Arm A - Control Arm | Incidence of Adverse Events (AEs) | Vomiting | 10 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Diarrhea | 13 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Nausea | 12 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Vomiting | 9 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Small Intestinal Obstruction | 16 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Hypertension | 15 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Fatigue | 10 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Abdominal pain | 7 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Rash maculo-papular | 9 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Anemia | 16 participants |
| Arm B - Experimental Arm | Incidence of Adverse Events (AEs) | Neutrophil count decreased | 8 participants |
Secondary
Objective Tumor Response Rate (Complete Response and Partial Response)
The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria.
Time frame: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B
Population: Randomized patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm A - Control Arm | Objective Tumor Response Rate (Complete Response and Partial Response) | 8 participants |
| Arm B - Experimental Arm | Objective Tumor Response Rate (Complete Response and Partial Response) | 34 participants |
Secondary
Overall Survival
Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact. Patients with disease progression on the Control arm were allowed to cross over to the trametinib arm. Per the protocol, the intent-to-treat OS analysis was not adjusted for crossover.
Time frame: Time from study entry to time of death or date of last contact, an average of 29 months for arm A and 37 months for arm B
Population: All randomized patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A - Control Arm | Overall Survival | 29.2 Months |
| Arm B - Experimental Arm | Overall Survival | 37.0 Months |
Secondary
Patient Reported Acute Peripheral Neuropathy Symptoms
Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggesting less peripheral neuropathy symptoms
Time frame: Up to 52 weeks
Population: Patients that provided baseline and ≥ 1 follow-up assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A - Control Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | 52 Weeks | 12.8 score on a scale | Standard Deviation 3.2 |
| Arm A - Control Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | 24 Weeks | 12.4 score on a scale | Standard Deviation 4 |
| Arm A - Control Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | Baseline | 13.2 score on a scale | Standard Deviation 3.5 |
| Arm A - Control Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | 12 Weeks | 12.5 score on a scale | Standard Deviation 4 |
| Arm A - Control Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | 36 Weeks | 12.3 score on a scale | Standard Deviation 3.8 |
| Arm B - Experimental Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | 24 Weeks | 12.1 score on a scale | Standard Deviation 4.2 |
| Arm B - Experimental Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | Baseline | 12.8 score on a scale | Standard Deviation 3.8 |
| Arm B - Experimental Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | 12 Weeks | 12.6 score on a scale | Standard Deviation 4.2 |
| Arm B - Experimental Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | 52 Weeks | 12.4 score on a scale | Standard Deviation 4.2 |
| Arm B - Experimental Arm | Patient Reported Acute Peripheral Neuropathy Symptoms | 36 Weeks | 12.6 score on a scale | Standard Deviation 3.9 |
Secondary
Patients Reported Acute Quality of Life
Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for ovarian cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). . The FACT-O TOI score is calculated as the sum of the subscale scores if more than 80% of the FACT-O TOI items provide valid answers and all of the component subscales have valid scores. The FACT-O TOI score ranges 0-100 with a large score suggesting better QOL. Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the quality of life endpoint definition
Time frame: 1. baseline (prior to cycle 1), 12 weeks (prior to cycle 4), 24 weeks (4 weeks post cycle 6), 36 weeks post cycle 1, 52 weeks post cycle 1.
Population: Patients who provided baseline and ≥ 1 follow-up assessment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm A - Control Arm | Patients Reported Acute Quality of Life | 52 Weeks | 72.1 score on a scale | Standard Deviation 16.9 |
| Arm A - Control Arm | Patients Reported Acute Quality of Life | 12 Weeks | 74.2 score on a scale | Standard Deviation 16 |
| Arm A - Control Arm | Patients Reported Acute Quality of Life | 24 Weeks | 70.2 score on a scale | Standard Deviation 15.5 |
| Arm A - Control Arm | Patients Reported Acute Quality of Life | 36 Weeks | 69.3 score on a scale | Standard Deviation 18.6 |
| Arm A - Control Arm | Patients Reported Acute Quality of Life | Baseline | 74.5 score on a scale | Standard Deviation 16.6 |
| Arm B - Experimental Arm | Patients Reported Acute Quality of Life | 36 Weeks | 72.6 score on a scale | Standard Deviation 12.8 |
| Arm B - Experimental Arm | Patients Reported Acute Quality of Life | 52 Weeks | 73.3 score on a scale | Standard Deviation 14.3 |
| Arm B - Experimental Arm | Patients Reported Acute Quality of Life | Baseline | 74.5 score on a scale | Standard Deviation 13.7 |
| Arm B - Experimental Arm | Patients Reported Acute Quality of Life | 24 Weeks | 73.0 score on a scale | Standard Deviation 12.8 |
| Arm B - Experimental Arm | Patients Reported Acute Quality of Life | 12 Weeks | 70.6 score on a scale | Standard Deviation 13.5 |
Secondary
pERK Expression
Will be quantified using the H-score derived from the immunohistochemistry analysis of patient tumor tissue and is expected to present as a continuous measure. will consider the prognostic and predictive abilities of pERK relative to objective response rate (ORR) or PFS. Analysis of the dichotomous markers will be supported by Kaplan Meier plots, and forest plots of the odds-ratio and hazard ratio estimates. Duration of response will be depicted using swimmer plots, with median duration estimated using Kaplan Meier methods. The multivariable models will include covariate adjustment for geographic region, performance status and number of prior regimens, presented using effect coding. The adjusted hazard- and odds- ratio estimates from the multivariable models will be supported by nominal p-values and 2-sided, 95% confidence intervals. Confidence intervals will be interpreted as the plausible range of values for the true (unobserved) ratio that is supported by the data.
Time frame: Baseline
Secondary
Progression Free Survival
Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan. RECIST v1.1 defines progression as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
Time frame: Time from study entry to time of progression or death, an average of 7 months for SOC and 13 months for the treatment (Trametinib) arm.
Population: Patients with sufficient tissue for analysis
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm A - Control Arm | Progression Free Survival | 13.2 Months |
| Arm B - Experimental Arm | Progression Free Survival | 11.4 Months |
| KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (Trametinib) | Progression Free Survival | 7.3 Months |
| KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (SOC) | Progression Free Survival | 6.3 Months |
95% CI: [0.28, 1.07]
95% CI: [0.39, 1.03]
Comparison: Prognostic effect of the mutation status among patients in the SOC arm.p-value: 0.092995% CI: [0.34, 1.08]Chi-squared
Comparison: Predictive effect biomarker p-valuep-value: 0.7195Chi-squared